nach oben

Erschienen in:

01.09.2012 | Case Report

Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review

verfasst von: Omer Celal Elcioglu, Abdullah Ozkok, Timur Selcuk Akpınar, Fatih Tufan, Murat Sezer, Sabahattin Umman, Sevgi Kalayoglu Besısık

Erschienen in: International Journal of Hematology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Tirofiban is a glycoprotein (GP) IIb/IIIa receptor antagonist used in the treatment of acute coronary syndrome (ACS). Thrombocytopenia is a well-known complication of GPIIb/IIIa inhibitors. Life-threatening complications such as alveolar and gastrointestinal system hemorrhages may occur in the course of thrombocytopenia. Platelet count should be monitored closely, including during the first few hours of the infusion. Adverse events may be prevented by prompt discontinuation of the therapy. Herein we present two cases of profound and sudden thrombocytopenia associated with tirofiban use in the treatment of ACS together with a review of the literature.

Karvouni E, Katritsis DG, Ioannidis J. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41:26–32.PubMedCrossRef

Huxtable LM, Tafreshi MJ, Rakkar ANS. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. J Am Coll Cardiol. 2006;97:426–9.

Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol. 2007;23(12):963–70.PubMedCrossRef

Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet. 2002;41:187–95.PubMedCrossRef

The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445–53.CrossRef

Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schömig A. Effects of platelet glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998;98:2695–701.PubMedCrossRef

The PRISM-PLUS investigators. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/Non-ST-elevation myocardial infarction. Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patient Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation. 2000;102:2466–72.CrossRef

Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, Huston M, Schreiber D, DiBatttiste PM, Yeung AC. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial. Circulation. 2003;107:1497–501.PubMedCrossRef

Topol EJ, Moliterno DJ, Herrmann HC, et al. for the TARGET investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888–94.PubMedCrossRef

10.

Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation. 2004;109:2203–6.PubMedCrossRef

11.

Ali A, Patil S, Grady KJ, Schreiber TL. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors. Catheter Cardiovasc Interv. 2000;49(2):181–4.PubMedCrossRef

12.

Patel S, Patel M, Din I, Reddy CVR, Kassotis J. Profound thrombocytopenia associated with tirofiban: case report and review of literature. Angiology. 2005;56:351–5.PubMedCrossRef

13.

Bugie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after the treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002;100:2071–6.

14.

Demirkan B, Guray Y, Guray U, Korkmaz S. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report. J Thromb Thrombolysis. 2006;22:77–8.PubMedCrossRef

15.

Mulot A, Moulin F, Fohlen-Walter A, Angioi M, Sghaier M, Carteaux JP, Lecompte T, de Maistre E. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment. Am J Hematol. 2004;77:67–71.PubMedCrossRef

16.

Eryonucu B, Tuncer M, Erkoc R. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. Cardiovasc Drugs Ther. 2004;18:503–5.PubMedCrossRef

17.

Dunkley S, Lindeman R, Evans S, Casten R, Jepson N. Evidence of platelet due to tirofiban-dependent platelet antibodies: double trouble. J Thromb Haemost. 2003;1(10):2248–50.PubMedCrossRef

18.

George JN, Aster NH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematol Am Soc Hematol Educ Program. 2009;1:153–8 (Review).

19.

Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357:580–7.PubMedCrossRef

20.

Aster RH, Curtis BR, Bougie DW. Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors. Semin Thromb Hemost. 2004;30(5):569–77. Review.PubMedCrossRef

21.

Billheimer JT, Dicker IB, Wynn R, Bradley JD, Cromley DA, Godonis HE, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood. 2002;99(10):3540–6.PubMedCrossRef

22.

George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osbome S, Vondracek T. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129(11):886–90.PubMed

23.

Andres E, Dali-Youcef N, Serraj K, Zimmer J. Recognition and management of drug-induced cytopenias: the example of idisyncratic drug-induced thrombocytopenia. Expert Opin Durg Saf. 2009;8(2):183–90.CrossRef

24.

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010;116(12):2127–33. Epub 2010 Jun 8.PubMedCrossRef

25.

Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest. 2005;127(2 suppl):53S–9S.PubMedCrossRef

26.

Becker PS, Miller VT. Heparin-induced thrombocytopenia. Stroke. 1989;20(11):1449–59.PubMedCrossRef

27.

Clofent-Sanchez G, Harizi H, Nurden A, Coste P, Jais C, Nurden P. A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunoglobulin G. J Thromb Haemost. 2007;5(5):1068–70.PubMedCrossRef

28.

Bosco A, Kidson-Gerber G, Dunkley S. Delayed tirofiban-induced thrombocytopenia: two case reports. J Thromb Haemost. 2005;3(5):1109–10.PubMedCrossRef

29.

Said SM, Hahn J, Schleyer E, Müller M, Fiedler GM, Buerke M, Prondzinsky R. Glycoprotein IIb/IIIa receptor inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol. 2007;96(2):61–9.PubMedCrossRef

30.

Sakellariou D, Pastromas S, Koulouris S, Manolis AS. First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia). Tex Heart Inst J. 2009;36(1):55–7.PubMed

31.

Lin YL, Chen LL, Luo YK, Zheng XC, Li WW. Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome. Acta Pharmacol Sin. 2009;30(5):553–8.PubMedCrossRef

32.

Guo J, Xu M, Xi Y. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J. 2012;39(1):99–103.PubMed

33.

Yilmaz MB, Akin Y, Biyikoglu SF, Guray U, Korkmaz S. Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication. Int J Cardiol. 2004;93(1):81–2.PubMedCrossRef

34.

Matsuno O, Okubo T, Hiroshige S, Takenaka R, Ono E, Ueno T, et al. Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med. 2007;212(1):49–53.PubMedCrossRef

35.

Saito M, Yagi M, Uno K, Takanaka K. Comparative study of the usefulness of the drug-induced lymphocyte stimulation test and the leukocyte migration test in drug allergies. Biol Pharm Bull. 2008;31(2):209–304.CrossRef

36.

Huynh T, Piazza N, DiBattiste PM, Snapinn SM, Wan Y, Pharand C, Theroux P. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptor blockade in patients with high-risk acute coronary syndromes: insights form the PRIM-PLUS study. Int J Cardiol. 2005;100:73–8.PubMedCrossRef

37.

Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 2000;140:206–11.PubMedCrossRef

38.

Tuhta AG, Yeşildağ O, Köprülü D. Tirofiban-associated acute thrombocytopenia. Acta Cardiol. 2006;61(5):577–9.PubMedCrossRef

39.

Rahman N, Jafary FH. Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction. Tex Heart Inst J. 2010;37(1):109–12.PubMed

Titel: Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review
verfasst von: Omer Celal Elcioglu
Abdullah Ozkok
Timur Selcuk Akpınar
Fatih Tufan
Murat Sezer
Sabahattin Umman
Sevgi Kalayoglu Besısık
Publikationsdatum: 01.09.2012
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 3/2012
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-012-1133-7

Springer Medizin

Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review

Abstract

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Development of a fibrous DNA chip for cost-effective β-thalassemia genotyping

Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan

Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression

Transient hemiparesis in a 14-year-old boy with MYH9 disorders

Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation

MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-Cm)-induced myeloid leukemia

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie